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Novel antiangiogenic strategies with comple-
mentary mechanisms are needed to maximize
efficacy and minimize resistance to current an-
giogenesis inhibitors. We explored the thera-
peutic potential and mechanisms of aPlGF,
an antibody against placental growth factor
(PlGF), a VEGF homolog, which regulates the
angiogenic switch in disease, but not in health.
aPlGF inhibited growth and metastasis of vari-
ous tumors, including those resistant toVEGF(R)
inhibitors (VEGFRIs), and enhanced the efficacy
of chemotherapy and VEGFRIs. aPlGF inhibited
angiogenesis, lymphangiogenesis, and tumor
cell motility. Distinct from VEGFRIs, aPlGF pre-
vented infiltration of angiogenic macrophages
and severe tumor hypoxia, and thus, did not
switch on the angiogenic rescue program re-
sponsible for resistance to VEGFRIs. Moreover,
it did not cause or enhance VEGFRI-related
side effects. The efficacy and safety of aPlGF,
its pleiotropic and complementary mechanism
to VEGFRIs, and the negligible induction of an
angiogenic rescue program suggest that aPlGF
may constitute a novel approach for cancer
treatment.
INTRODUCTION
Antiangiogenic agents prolong the survival of cancer pa-
tients, however, without cure and at the expense of side
effects (Hurwitz et al., 2004; Kramer and Lipp, 2007).
The role of VEGF and VEGFR-2 in tumor growth is wellestablished, but other angiogenic factors switch on during
cancer progression and induce resistance to VEGFRI
monotherapy. By reducing tumor angiogenesis and in-
creasing hypoxia, VEGFRIs rescue angiogenesis via other
angiogenic factors. Combination therapy of antiangio-
genic agents with complementary mechanisms could
reduce resistance but might increase toxicity.
PlGF is a pleiotropic cytokine that stimulates endothelial
cell (EC) growth, migration, and survival; chemoattracts
angiocompetent macrophages and bone marrow progen-
itors; and determines the metastatic niche. Unlike VEGF,
PlGF selectively binds VEGFR-1 and its coreceptors neu-
ropilin-1 and -2. Besides indirect effects (Park et al.,
1994), PlGF signals directly via VEGFR-1, thus, acting in-
dependently of VEGF in ECs, macrophages, bone marrow
progenitors, and tumor cells, which primarily express
VEGFR-1 (Clauss et al., 1996; Hattori et al., 2002; Kaplan
et al., 2005).
PlGF stimulates angiogenesis, leukocyte infiltration,
tumor growth and stromal cell migration (Luttun et al.,
2002a; Marcellini et al., 2006; Roy et al., 2005), and revas-
cularization of ischemic tissues (Luttun et al., 2002b), indi-
cating that PlGF hasbiological activity in vivo. An anti-PlGF
antiserum inhibits tumor cell invasion in vitro (Taylor and
Goldenberg, 2007) and vascular leakage in vivo (Carmeliet
et al., 2001), while PlGF overexpressing tumors grow less
in VEGFR-1/TK/mice (Hiratsuka et al., 2001). However,
genetic studies show that PlGF is redundant for vascular
development and maintenance, but contributes to the
angiogenic switch in disease (Carmeliet et al., 2001; Rakic
et al., 2003). This raised the question whether PlGF inhibi-
tors might reduce pathological angiogenesis but, unlike
VEGFRIs, without affecting healthy blood vessels, and
thus provide an attractive drug with a better safety profile.
PlGF levels in plasma and tumors correlate with tumor
stage, vascularity, recurrence, metastasis, and survival
in various tumors (Chen et al., 2004; Ho et al., 2007;Cell 131, 463–475, November 2, 2007 ª2007 Elsevier Inc. 463
Figure 1. Characterization of aPlGF
(A) aPlGF inhibits binding of PlGF to VEGFR-1
(ELISA; n = 8).
(B) Inhibition of PlGF-induced VEGFR-1 tyro-
sine phosphorylation in 293T cells by aPlGF.
*p < 0.05 versus control; #p < 0.05 versus PlGF.
(C and D) Migration of PlGF/ endothelial (C)
or Panc02 tumor cells (D) in response to PlGF
or VEGF (each at 50 ng/ml), assessed in the
presence or absence of a 100-fold molar ex-
cess of aPlGF or IgG1. The number of migrated
cells per high-power optical field (OF) are
shown (n = 5; *p < 0.05 versus control [0.1%
FBS]); #p < 0.05 versus PlGF. Error bars repre-
sent mean ± SEM.Matsumoto et al., 2003; Parr et al., 2005; Wei et al., 2005).
Notably, PlGF is upregulated in cancer patients treated
with VEGFRI therapy (Motzer et al., 2006; Rosen et al.,
2007; Willett et al., 2005), as well as in human tumors after
radio-immunotherapy (Taylor et al., 2003), suggesting
a key role of PlGF in the angiogenic rescue. Here, we gen-
erated a neutralizing aPlGF and evaluated its therapeutic
potential and mechanism of action in the inhibition of solid
tumor growth.
RESULTS
Characterization of an Anti-PlGF Antibody
Wedeveloped a neutralizingmurine anti-PlGFmonoclonal
antibody (clone 5D11D4; referred to as aPlGF) that specif-
ically recognizes mouse PlGF-2 (all mouse proteins de-
noted without prefix; human proteins are preceded with
‘‘h’’) with a high affinity (KD = 7.0 3 10
10 M). aPlGF in-
hibited the binding of PlGF to VEGFR-1 (IC50: 27 pM)
and neuropilin-1, tyrosine phosphorylation of VEGFR-1
in response to PlGF, and the response of endothelial
and tumor cells to PlGF, without, however, inhibiting the
binding or activity of VEGF or other related factors (Figures
1A–1D; Figures S1A–S1F in the Supplemental Data avail-
able with this article online).
Effect of aPlGF on Tumor Growth and Metastasis
PlGF was undetectable in most healthy tissues but in-
duced by hypoxia, abundant in all tumors analyzed and
expressed by both tumor and stromal cells (Figures S1G464 Cell 131, 463–475, November 2, 2007 ª2007 Elsevier Inc.and S1H; data not shown). When injecting B16 melanoma
cells subcutaneously or pancreatic Panc02 tumor cells
orthotopically, aPlGF dose-dependently inhibited tumor
growth (Figures 2A–2D) and reduced the incidence of
local tumor invasion, bile duct stenosis and hemorrhagic
ascites (n = 65–71; Table S1; for pharmacokinetics and ra-
tionale of dosing, see Note S1). aPlGF dose-dependently
inhibited metastasis of Panc02 tumors to regional and
distant lymph nodes, independent of primary tumor size
(Figures 2E–2G; Note S2). Metastasis to lymph nodes
occurred in >78% of control mice, while only in 29% of
aPlGF-treated mice (n = 18; p < 0.05; Table S1). Overall,
aPlGF inhibited the growth and/or metastasis of 12 differ-
ent tumor models tested, mostly by 55% to 66% (Fig-
ures 2H and 2I; Table S2), including human xenograft
tumors (data not shown). aPlGF also suppressed the
growth of established B16 tumors (by 35%) and the lodg-
ing of intravenously injected B16 tumor cells (by 50%; data
not shown).
To evaluate how efficiently aPlGF inhibited tumor
growth as compared to established VEGFRIs, we used
an anti-VEGFR-2 antibody (aVEGFR-2). Compared to
aVEGFR-2, aPlGF comparably inhibited the growth of
B16 tumors (Figure 2J) or was less effective in inhibiting
growth of Panc02 tumors, a VEGFRI-sensitive model (by
62 ± 3% versus 82 ± 2%; n = 45; p < 0.05). Interestingly,
however, aPlGFwasmore effective in suppressing growth
of CT26 tumors, a model relatively resistant to VEGFRIs
(by 56 ± 3% versus 31 ± 4%; n = 90; p < 0.05; see also
Figure 3D). Similar results were obtained when using other
Figure 2. aPlGF Inhibits Tumor Growth
and Metastasis of Syngeneic Tumors
(A–G) aPlGF dose dependently inhibits s.c.
B16 (N = 15) (A), and orthotopic Panc02 tumor
growth (n = 10) (B–D) and lymphatic metastasis
(n = 9–11) (G). Compared to control (C and E),
aPlGF inhibits growth of primary Panc02 tu-
mors (pT) (D) and metastasis of celiac (D) and
mesenteric (F) lymph nodes (LN; arrows).
(H and I) aPlGF inhibits growth of syngeneic
s.c. Panc02 (H) and CT26 (I) tumors (n = 10).
(J) aPlGF and aVEGFR-2 comparably inhibit
B16 tumor growth (n = 15). *p < 0.05 versus
control. Error bars represent mean ± SEM.VEGFRIs (see below). Thus, aPlGF inhibited the growth of
VEGFRI-sensitive but also of VEGFRI-resistant tumors.
aPlGF Enhances the Efficacy of Chemotherapy
Exposure of Panc02 and B16 tumor cells to the cytostatic
agents gemcitabine and cyclophosphamide dose-depen-
dently increased PlGF expression (Figure 3A; Figure S2A),
providing a rationale to test whether aPlGF would en-
hance chemotherapy. Compared tomonotherapy, combi-
nation therapy with aPlGF and gemcitabine inhibited
Panc02 tumor growth more (Figure 3B). In the B16 model,
aPlGF plus cyclophosphamide near completely inhibited
tumor growth as compared to only the partial inhibition
of tumor growth by eithermonotherapy alone (Figure S2B).
Thus, aPlGF enhanced the tumor growth inhibitory effect
of cytostatic agents.
aPlGF Enhances the Anticancer Activity
of aVEGFR-2
VEGFR blockade increases plasma PlGF levels in cancer
patients (Motzer et al., 2006; Rosen et al., 2007; Willettet al., 2005). Plasma PlGF levels were undetectable in
healthymice, but elevated to100 pg/ml in tumor-bearing
mice (Figure 3C). Treatment of tumor-bearing mice with
aVEGFR-2 elevated PlGF levels in the plasma (Figure 3C)
and tumors (Note S3A). Plasma VEGF levels were also
increased when tumor-bearing mice were treated with
aVEGFR-2 (Figure S2C), but not by aPlGF (data not
shown). ELISA confirmed that tumoral VEGF levels were
upregulated in tumors by aVEGFR-2, but not by aPlGF
(Note S3B).
The finding that PlGF levels were upregulated by
aVEGFR-2 in tumor-bearing mice prompted us to ex-
amine whether aPlGF enhanced the antitumor effect of
aVEGFR-2, using the colon CT26 tumor model, as it is rel-
atively resistant to aVEGFR-2 (see above). Compared to
the partial inhibition of tumor growth by monotherapy
with aVEGFR-2 or aPlGF, their combination inhibited tu-
mor growth more completely (Figure 3D), indicating that
aPlGF enhanced the antitumor activity of aVEGFR-2.
We also examined whether aPlGF might substitute for
aVEGFR-2. A maximal dose of aPlGF and aVEGFR-2Cell 131, 463–475, November 2, 2007 ª2007 Elsevier Inc. 465
Figure 3. aPlGF Enhances Chemother-
apy and aVEGFR-2 Therapy
(A) Gemcitabine upregulates PlGF release by
Panc02 tumor cells (n = 5).
(B) Panc02 tumor-bearing mice received
aPlGF (50 mg/kg), gemcitabine (125 mg/kg,
two times per week) or the combination. Com-
bination therapy inhibited tumor growth more
than single treatments (n = 15; #p < 0.01 versus
single treatments, ANOVA). Arrow indicates
start of treatment.
(C) aVEGFR-2 increases PlGF plasma levels
in CT26, B16 and Panc02 tumor bearing mice
(n = 5–11).
(D) CT26 tumor growth curves inmice receiving
aPlGF (50 mg/kg), aVEGFR-2 (50 mg/kg) or the
combination of both. aPlGF enhances
aVEGFR-2 (n = 15; #p < 0.0001 versus single
treatments, ANOVA). Arrow indicates start of
treatment.
(E) aVEGFR-2 dose dependently inhibits
growth of orthotopic Panc02 tumors (n = 12).
Substitution of aVEGFR-2 (5 mg/kg) by aPlGF
(50 mg/kg) inhibits tumor growth to the same
extent as 40 mg/kg aVEGFR-2 (n = 12; #p <
0.05 versus aVEGFR-2 (5 mg/kg) and p <
0.05 versus aPlGF).
(F) Partial substitution of aVEGFR-2 by aPlGF
reduces mesenteric lymph node metastasis
as compared to single treatments (n = 12;
#p < 0.05 versus aPlGF and aVEGFR-2). *p <
0.05 versus control. Error bars represent
mean ± SEM.reduced tumor growth in Panc02 tumors by 56% and
83%, respectively (Figure 3E). A low dose of aVEGFR-2
(from here on defined as 5 mg/kg; three times per week)
inhibited tumor growth by 30%, but when combined
with aPlGF, tumor growth was reduced by 83%, i.e., to
the same extent as monotherapy with a high dose of
aVEGFR-2 (Figure 3E). Similar results were obtained
when analyzing lymphatic metastasis of Panc02 tumor
cells, whereby substitution ofmost of aVEGFR-2 by aPlGF
yielded even more complete suppression than aVEGFR-2
monotherapy alone (Figure 3F). Thus, substitution of
aVEGFR-2 with aPlGF resulted in a comparable or even
greater antitumor/metastasis effect.
aPlGF Inhibits Tumor Angiogenesis
aPlGF reduced tumor angiogenesis by50% in all tumors
analyzed, i.e., comparably or slightly less than aVEGFR-2
(Figure 4A; Figures S3A–S3F; Table S3). Double staining
for CD31 and caspase-3 revealed that aPlGF induced
EC apoptosis, indicating that aPlGF induced pruning of
preexisting tumor vessels (Figures 4B–4D). In Panc02 tu-466 Cell 131, 463–475, November 2, 2007 ª2007 Elsevier Inc.mors, a combination of aPlGF with a low dose aVEGFR-2
reduced tumor angiogenesis to the same extent as a high
dose of aVEGFR-2 (Figure 4A). Also, in CT26 tumors, the
combination of aPlGF plus aVEGFR-2 yielded the greatest
inhibition of tumor angiogenesis (Figure S3G). Thus,
aPlGF reduces tumor growth, at least in part, by inhibiting
tumor angiogenesis. Similar to aVEGFR-2, aPlGF primar-
ily reduced EC numbers, without affecting SMC counts,
suggesting possible improvement of tumor vessel matura-
tion (Figures 4E–4H).
aPlGF Inhibits Intratumoral Macrophage
Recruitment
VEGFR-1+ macrophages promote tumor growth and
angiogenesis. aPlGF reduced F4/80+ macrophage infiltra-
tion,maximally by 74%, in both VEGFRI-sensitive (Panc02;
Figure 4I) and VEGFRI-resistant (CT26; Figures S4A, S4B,
and S4E) tumors (Table S3). It also normalized circulating
monocyte counts in these tumor models (Figure 4J; Table
S3). In contrast, aVEGFR-2 failed to inhibit the macro-
phage infiltration and even slightly increased circulating
Figure 4. aPlGF Inhibits Tumor Angiogenesis and Macrophage Recruitment
(A) Quantification of CD31+ vessel density of orthotopic Panc02 tumors treated with control IgG1, aPlGF, and/or aVEGFR-2. Combination of aVEGFR-
2 (5 mg/kg) with aPlGF (50 mg/kg) inhibits angiogenesis comparably as 40 mg/kg aVEGFR-2 (n = 6; p = NS) and more efficiently than either aPlGF or
5 mg/kg aVEGFR-2 (n = 6; #p < 0.05).
(B and C) Double staining using anti-CD31 (green) and anti-caspase-3 (red) antibodies on orthotopic Panc02 tumors treated with control IgG1 (B) and
aPlGF (C). Arrowhead indicates apoptotic EC.
(D) Bar graph represents percent of apoptotic EC area/total EC area (n = 8).
(E–H) Double staining for CD31 (green) and SMA (red) on Panc02 tumor sections after treatment with control IgG1 (E), aPlGF (F) and aVEGFR-2 (G),
and quantification of CD31+ and SMA+ area/tumor area (H). Both aPlGF and aVEGFR-2 decrease CD31+ areas without affecting SMA+ areas (n = 6).
Scale bar is 100 mm.
(I and J) aPlGF, but not aVEGFR-2, inhibits intratumoral macrophage recruitment (n = 10) (I) and abrogates Panc02 tumor-induced bloodmonocytosis
(n = 6; xp < 0.05 versus nontumor-bearingmice) (J). aPlGF predominates over aVEGFR-2 treatment (n = 6–10). #p < 0.05 as indicated. *p < 0.05 versus
control. Error bars represent mean ± SEM.monocytecounts (Figures4I and4J;FiguresS4CandS4E).
Interestingly, the combination of aPlGF plus aVEGFR-2
inhibited macrophage infiltration and normalized tumor-
induced monocytosis (Figures 4I and 4J; Figures S4D and
S4E), indicating that aPlGFpredominated over aVEGFR-2.
Thus, aPlGF and aVEGFR-2 substantially differ in their
mechanism of regulating tumor inflammation. Similar
findings were obtained when using a VEGF inhibitor (see
below).
PlGF-Dependent Macrophage Recruitment
Confers Resistance to aVEGFR-2
CT26 tumors produced comparable amounts of VEGF and
PlGF (data not shown), yet aVEGFR-2 inhibited their
growth much less than aPlGF (see above). Since both an-
tibodies comparably inhibited angiogenesis, the resis-
tance ofCT26 tumors toaVEGFR-2 could not be explained
by its antiangiogenic activity alone. As aPlGF, but not
aVEGFR-2, inhibitedmacrophage infiltration,weassessed
whether the tumor responsiveness to aVEGFR-2 was de-
pendent on tumor inflammation. We therefore used clodr-
onate liposomes (referred to as clodrolip) to deplete mac-
rophages (Zeisberger et al., 2006). Clodrolip slowed downtumor growth in controlmicebut did not enhance the effect
of aPlGF (Figure 5A). aPlGF alone was equipotent in inhib-
iting intratumoral macrophage infiltration, and clodrolip
only slightly amplified the anti-inflammatory effect of
aPlGF (Figure 5B). Tumor angiogenesis was reduced by
clodrolip, indicating that macrophages were proangio-
genic (Figure 5C). However, clodrolip did not further am-
plify the antiangiogenic effect of aPlGF, suggesting that
aPlGF alone already efficiently depleted growing tumors
from proangiogenic macrophages (Figure 5C). The finding
that aPlGF inhibited tumor growth and angiogenesis more
than clodrolip, while comparably inhibiting intratumoral
macrophage infiltration, suggests that aPlGF inhibits
tumor growth not only via an anti-inflammatory activity, but
also via its antiangiogenic activity. Similar results were
observed in orthotopic Panc02 tumors (Figures S4F–S4H).
In contrast, the combination of aVEGFR-2 and clodrolip
was more effective in inhibiting tumor growth, indicating
that depletion of mononuclear cells by clodrolip sensitized
CT26 tumors to the inhibitory effect of aVEGFR-2 (Fig-
ure 5D). Since aVEGFR-2 inhibited tumor angiogenesis
without affecting tumor macrophage infiltration and clo-
drolip amplified the antiangiogenic activity of aVEGFR-2Cell 131, 463–475, November 2, 2007 ª2007 Elsevier Inc. 467
Figure 5. Macrophage Recruitment
Confers Resistance to aVEGFR-2
(A–C) Macrophage depletion by clodrolip in-
hibits tumor growth but does not further en-
hance the antitumor effect of aPlGF (n = 15)
(A) because the latter depletes tumors already
from macrophages (n = 15) (B). Macrophage
depletion inhibits angiogenesis but does not
further enhance the antiangiogenic effect of
aPlGF (n = 5) (C). Note that aPlGF inhibits tu-
mor growth (A) and angiogenesis (C) more
than clodrolip. #p < 0.05.
(D–F) Clodrolip enhances the antitumor effect
of aVEGFR-2 (n = 15) (D) by depleting tumor
macrophages (N = 6) (E), and by inhibiting
tumor angiogenesis (n = 5) #p < 0.05 versus
aVEGFR-2 alone (F).
(G–I) LYVE-1+ immunostaining of peritumoral
lymphatic vessels in Panc02 tumors treated
with control IgG1 (G) or aPlGF (H). Scale bar
is 100 mm. aPlGF and aVEGFR-2 (40mg/kg) in-
hibit peritumoral lymphatic vessel density (I).
Combination of aVEGFR-2 (5 mg/kg) and
aPlGF reduces lymphatic vessel density more
than single treatments (n = 7; #p < 0.05).
(J–L) Clodrolip and aPlGF reduce intratumoral
VEGF-C transcript levels (J), lymphatic vessel
density (K) and lymph node metastasis (L)
comparably (n = 15). *p < 0.05 versus control.
Error bars represent mean ± SEM.(Figures 5E and 5F), the infiltration of proangiogenic mac-
rophages contributed to the resistance of CT26 tumors to
aVEGFR-2. Thus, aPlGF and aVEGFR-2 act via distinct
mechanisms: by blocking both tumor angiogenesis and
inflammation, aPlGF inhibits growth of a VEGFRI-resistant
tumor; in contrast, the antiangiogenic activity of aVEGFR-
2 is unable to suppress growth of this VEGFRI-resistant
tumor, since it fails to inhibit infiltration of proangiogenic
macrophages.
aPlGF Inhibits Tumor Lymphangiogenesis
To explain howaPlGF inhibited lymphaticmetastasis of or-
thotopicPanc02 tumors,weanalyzed lymphangiogenesis.
aPlGF reduced LYVE-1+ peritumoral lymphatic vessel
density and area by 75% and 87%, respectively (Figures
5G–5I; Figure S3H). Consistent with previous findings
that VEGF stimulates lymphangiogenesis, aVEGFR-2
also inhibited lymphangiogenesis in Panc02 tumors (Fig-
ure 5I). Notably, combination of a low dose of aVEGFR-2468 Cell 131, 463–475, November 2, 2007 ª2007 Elsevier Inc.plus aPlGF resulted in a significantly greater inhibition of
lymphangiogenesis than single treatments (Figure 5I).
Thus, both aPlGF and aVEGFR-2 suppressed peritumoral
lymphangiogenesis and amplified each other’s antilym-
phangiogenic activity. Since lymphatic endothelial cells
do not express VEGFR-1, we studied if aPlGF inhibited
lymphangiogenesis indirectly. Indeed, aPlGF decreased
Vegf-C levels, lymphangiogenesis, and lymph node me-
tastasis comparably as clodrolip, suggesting that aPlGF
inhibited the recruitment of prolymphangiogenic macro-
phages (Figures 5J–5L).
Negligible Induction of a Rescue Angiogenic
Program by aPlGF
Resistance to antiangiogenic agents is, at least in part, de-
termined by the induction of a compensatory angiogenic
program. We therefore analyzed the tumor expression of
several angiogenic genes. Treatment of VEGFRI-sensitive
and -resistant tumor-bearing mice with aVEGFR-2, but
Figure 6. aPlGF Does Not Rescue
Angiogenesis and Enhances VEGF Trap
Therapy
(A) aPlGF does not induce angiogenic gene ex-
pression in contrast to aVEGFR-2. Data are
fold change over control (n = 3–5; see Note
S4 for absolute values).
(B–E) Immunostaining for hypoxyprobe-1onor-
thotopic Panc02 tumors treated with control
IgG1 (B),aPlGF (C), oraVEGFR-2 (40mg/kg) (D).
Scale bar is 200 mm. aVEGFR-2, but not aPlGF,
induces tumor hypoxia (n = 10; #p < 0.05 versus
aPlGF) (E).
(F and G) aPlGF enhances sFlk1 therapy on
tumor growth (F) and lymphatic metastasis (G)
in orthotopic Panc02 tumors (n = 15; #p < 0.05
versus aPlGF and sFlk1).
(H and I) Macrophages confer resistance to
sFlk1 in CT26 tumors. CT26 are resistant to
sFlk1 (H), but depletion of macrophages by clo-
drolip enhances the antitumor effect of sFlk1
(n= 15) (I). *p < 0.05 versus control. Error bars
represent mean ± SEM.not aPlGF, upregulated proangiogenic genes such as Sdf-
1, Fgf-1, Fgf-2, Vegf, Plgf, Mmp9, and Cxcl1 (Figure 6A).
This upregulation was specific, as other genes involved
in angiogenesis, such as Csf, Ccl-2, Egf, and Vegfr-3,
were not upregulated (data not shown). Tumor hypoxia,
resulting from the antiangiogenic treatment, may underlie
the induction of such an angiogenic rescue program. We
therefore assessed tumor hypoxia by staining for the
hypoxia-marker pimonidazole (PIMO; Figures 6B–6D). In
orthotopic Panc02 tumors, aVEGFR-2 (but not aPlGF)
significantly increased the PIMO+ fraction of the tumor
(Figure 6E). Further, aVEGFR-2 reduced the vessel area
more than aPlGF (lumen/tumor area: 4.6 ± 0.4% in con-
trols versus 3.3 ± 0.4% after aPlGF and 1.2 ± 0.2% after
aVEGFR-2; n = 5; p = 0.04 versus aPlGF; p < 0.0001 ver-
sus aVEGFR-2). In addition, aVEGR-2, but not aPlGF,
reduced in vivo tumor perfusion (tumor/kidney perfusion:
48 ± 10% in controls versus 17 ± 3% after aVEGFR-2,
n = 14; p < 0.01; and 45 ± 9% after aPlGF, n = 14; p =
NS). Similarly, in CT26 tumors, aVEGFR-2 caused more
tumor cell hypoxia than aPlGF, resulting in larger necrotic
tumor areas (Figures S4I and S4J). Thus, compared toaVEGFR-2, aPlGF caused less severe intratumoral hyp-
oxia, which may explain the minimal rescue angiogenic
program.
aPlGF Enhances VEGF-Trap Therapy
To assess whether aPlGFmechanistically also differs from
a specific VEGF inhibitor, we used a soluble form of
VEGFR-2 (sFlk1) that ‘‘traps’’ VEGF selectively (i.e., thus,
not PlGF or VEGF-B). Upon hydroporation, circulating
sFlk1 was elevated during the entire experiment to levels
(2,900 ± 790 ng/ml), previously reported to inhibit tumor
growth (Davidoff et al., 2002). sFlk1 inhibited orthotopic
Panc02 tumor growth, angiogenesis, and lymph nodeme-
tastasis (Figures 6F and 6G; Table S4) with plasma sFlk1
levels correlating with tumor growth inhibition (data not
shown). The combination of aPlGF with sFlk1 was more
efficient in inhibiting tumor growth and lymphatic metasta-
sis than each treatment alone (Figures 6F and 6G). When
using VEGFRI-resistant CT26 tumors, sFlk1 inhibited
tumor growth only insignificantly by 20% (Figure 6H) with-
out any correlation between sFlk1 levels and tumor inhibi-
tion, confirming that this tumor is resistant to VEGFRICell 131, 463–475, November 2, 2007 ª2007 Elsevier Inc. 469
Figure 7. aPlGF Does Not Affect Healthy
Vessels
(A–D) Immunofluorescent pictures of isolectin
perfused tracheas of mice treated with control
IgG1 (A), aPlGF (B), or aVEGFR-2 (C) reveal that
aVEGFR-2, but not aPlGF, induces tracheal
vessel regression (n = 14). Combination of
aPlGF and aVEGFR-2 does not further reduce
capillary branching points/mm2 compared to
aVEGFR-2 alone (n = 14; #p = NS versus
aVEGFR-2) (D). Scale bar is 100 mm.
(E) aPlGF does not upregulate plasma PAI-1
levels in healthy mice (n = 5). White and gray
bars represent murine and rat IgG1, respec-
tively.
(F) Mice were treated with aPlGF, aVEGFR-2,
or control IgG1 throughout pregnancy, and
body weight was monitored. aVEGFR-2, but
not aPlGF, arrests pregnancy and embryonic
development from day E7 onward (n = 10).
(G and H) Upon resection at day E8, the uteri of
mice treated with aVEGFR-2 contained dead
early stage embryos (n = 10) (G), whereas
aPlGF did not impair embryonic development
(n = 10) (H). *p < 0.05 versus control. Error
bars represent mean ± SEM.therapy. Similar to aVEGFR-2, sFlk1 inhibited tumor an-
giogenesis but failed to inhibit intratumoral macrophage
recruitment (Table S4), while clodrolip rendered this tumor
again sensitive to sFlk1 (Figure 6I). Thus, even despite its
antiangiogenic activity, sFlk1, like aVEGFR-2, is unable to
inhibit macrophage recruitment and, hence, CT26 tumor
growth. aPlGF, by contrast, differs from these VEGFRIs
by inhibiting angiogenesis and macrophage infiltration
and, thereby, growth of this VEGFRI-resistant tumor. Un-
like aPlGF, sFlk1 also switched on an angiogenic rescue
program, including Vegf, Plgf, and Fgf-2 (data not shown).
Safety Profile of the aPlGF Antibody
Treatment with VEGFRIs causes thrombosis, hyperten-
sion, microvascular pruning in healthy organs, interruption
of pregnancy, and other side effects (Hurwitz et al., 2004;
Kamba et al., 2006; Kramer and Lipp, 2007). However,
treatment of healthy mice with aPlGF did not affect body
weight, did not cause any obvious organ pathology upon
inspection and histological analysis, did not alter the clini-
cal chemistry or hematological blood profile, and did not
increase proteinuria (data not shown). When analyzing470 Cell 131, 463–475, November 2, 2007 ª2007 Elsevier Inc.the morphology of quiescent vessels in different healthy
organs, treatment with aVEGFR-2, but not aPlGF, for 3
weeks reduced the number of capillary branching points/
mm2 in the trachea by 34 ± 2% (Figures 7A–7C) and capil-
lary profiles/mm of follicle perimeter in the thyroid gland by
21 ± 1% (n = 14; p < 0.05; Table S5). Moreover, the combi-
nation of aPlGF and aVEGFR-2 did not aggravate the ad-
verse effect of aVEGFR-2 on vessel pruning (Figure 7D).
Thus, aPlGF enhanced the antitumor growth efficacy of
aVEGFR-2 without, however, aggravating its toxicity.
We also measured the circulating levels of plasminogen
activator inhibitor-1 (PAI-1), a fibrinolytic inhibitor of clot
lysis, released by stressed ECs and known risk factor of
thrombosis. Treatment with aVEGFR-2, but not aPlGF,
caused a 2.7-fold increase of PAI-1 levels (n = 5; p <
0.05; Figure 7E). Furthermore, after 3 weeks of treatment,
the mean blood pressure was elevated in mice given
aVEGFR-2 (73 ± 3.2 mmHg after IgG1 versus 95 ± 3.9
mmHg after aVEGFR-2; n = 9; p < 0.002), but not aPlGF
(74 ± 5.3 mmHg after IgG1 versus 74 ± 3.9 mmHg after
aPlGF; n = 9; p = NS). The relative teratogenicity of aPlGF
and aVEGFR-2 was analyzed in pregnant mice from the
day of plug-check throughout pregnancy. Mice treated
with aVEGFR-2 failed to gain weight beyond day 6, sug-
gesting that embryonic development was arrested (Fig-
ure 7F). At day 8 of pregnancy, their uteri contained dead,
partially resorbed early-stage embryos and a pale pla-
centa, indicating that aVEGFR-2 inhibited placental vascu-
lar development (Figures 7G and 7H). In contrast, aPlGFdid
not interrupt the pregnancy-associatedweight gain, nor did
it abort embryonic development, and resulted in normal
litters and healthy pups, that grew up normally (Table S5).
In contrast to aVEGFR-2, aPlGF did also not aggravate
the cardiotoxicity induced by doxorubicin (data not shown).
sFlk1 and VEGFR tyrosine kinase inhibitors had a compara-
ble toxicity profile to aVEGFR-2 (data not shown).
DISCUSSION
The primary findings of this study are (1) aPlGF monother-
apy inhibits the growth and metastasis of >12 different
tumor models; (2) cytotoxic drugs upregulate PlGF ex-
pression by tumor cells, and aPlGF amplifies the antitu-
mor effect of chemotherapy; (3) aVEGFR-2 and sFlk1 ther-
apy upregulate PlGF levels, and aPlGF enhances and
partially substitutes aVEGFR-2 and sFlk1 monotherapy;
(4) aPlGF mimics aVEGFR-2 and sFlk1 in inhibiting
tumor angiogenesis but differs by inhibiting intratumoral
macrophage infiltration and acts, thus, via complemen-
tary mechanisms to VEGFRIs; (5) unlike aVEGFR-2, aPlGF
does not induce an angiogenic rescue/antiangiogenic es-
cape program (which might lead to resistance against
antiangiogenic therapy) because it inhibits macrophage
infiltration and does not cause severe hypoxia; and (6)
aPlGF is not associated with typical VEGFRI side effects
but exhibits a superior safety profile. This study is the first
to document the pharmacological properties of a specific
PlGF-inhibitor (Note S5).
Mechanisms of aPlGF
The antitumor activity of aPlGF depends, in part, on its
pleiotropic effects. First, PlGF stimulates EC growth and
migration (Autiero et al., 2003; Carmeliet et al., 2001),
mobilizes angiocompetent bone marrow progenitors
(Hattori et al., 2002; Kaplan et al., 2005), and acts as a sur-
vival factor for existing vessels. Thus, aPlGF not only in-
hibits new vessel growth, but also causes regression of
existing tumor vessels. Second, aPlGF impaired tumor
lymphangiogenesis. Our finding that aPlGF augmented
the antilymphangiogenic activity of aVEGFR-2 suggests
that it acts via complementary VEGF-unrelated mecha-
nisms. Indeed, consistent with the role of macrophages
in pathological lymphangiogenesis (Cursiefen et al.,
2004), clodrolip inhibited lymphatic metastasis, lymphan-
giogenesis, and tumoral Vegf-C levels as effectively as
aPlGF, indicating that the effect of aPlGF on lymphatic
vessels is mainly mediated via macrophage inhibition.
An inflammation-dependent role of PlGF in lymphangio-
genesis might explain why PlGF/ mice do not exhibit
spontaneous lymphatic defects (Carmeliet et al., 2001).Third,aPlGF isanti-inflammatory, consistentwith the fact
that PlGF chemoattracts VEGFR-1+ macrophages (Luttun
et al., 2002a; Pipp et al., 2003). Tumor-associated macro-
phages (TAMs) participate in angiogenesis by secreting an-
giogenic factors or indirectly by producing proteases that
release sequestered angiogenic factors. An increase in
TAMs is associated with tumor progression, metastasis,
and poor prognosis, both in humans as well as in various
implanted or spontaneously arising tumor models in mice
(Pollard, 2004). Thus, by inhibiting their recruitment, aPlGF
also inhibits tumor growth. Whether aPlGF also blocks the
role of macrophages in establishing the premetastatic
niche, as suggested by genetic data using VEGFR-1/TK/
mice (Hiratsuka et al., 2002), remains to be established.
Another mechanism of aPlGF may relate to its cytostatic
activity for malignant cells (data not shown). The relative
role of the antiangiogenic, antilymphangiogenic, anti-in-
flammatory, and cytostatic activity of aPlGF in spontane-
ously arising tumor models in transgenic mice is currently
under investigation. Initial findings that loss of PlGF inhibits
carcinogen-induced skin cancer growth promise to use
such models to evaluate the activity of aPlGF.
Our data also indicate that aPlGF, by inhibiting macro-
phage recruitment, enhances the responsiveness of
tumors to VEGFRIs. Indeed, CT26 tumors are relatively re-
sistant to aVEGFR-2 and sFlk1, but, following macro-
phage depletion, they became sensitive to these VEGFRIs.
Thus, macrophages counteract VEGFRIs, presumably by
releasing angiogenic factors other than VEGF. Since mac-
rophages do not express VEGFR-2 (Clauss et al., 1996),
aVEGFR-2 failed to inhibit macrophage tumor infiltration.
sFlk1 was also ineffective—this is perhaps more surpris-
ing, as VEGF also chemoattracts macrophages. However,
aVEGFR-2 and sFlk1 also upregulated the expression of
the macrophage chemoattractants PlGF, VEGF, FGF-2,
and G-CSF, whichmight have counteracted VEGFRI treat-
ment. Thus, by blocking macrophage infiltration, aPlGF
not only reduced tumor growth, but also rendered tumors
more responsive to VEGFRIs.
Enhancement of Chemotherapy and VEGFR
Inhibitor Therapy by aPlGF
Like bevacizumab in patients (Hurwitz et al., 2004), aPlGF
amplified the effect of chemotherapy in preclinical mouse
tumor models. This may, at least in part, be attributable to
the fact that cytotoxic agents upregulate PlGF in tumor
cells. Obviously, additional mechanisms might contribute.
For instance, it remains to be determined whether the ef-
fects of aPlGF on tumor vessel perfusion will improve the
delivery of cytotoxic drugs, or whether aPlGF might also
inhibit EPC mobilization in response to chemotherapy.
Treatmentwith a single antiangiogenic agentmay lead to
acquired drug resistance based on an escape mechanism
via induction of an angiogenic rescue program; for in-
stance, FGF is upregulated after aVEGFR-2 treatment (Ca-
sanovas et al., 2005). Plasma PlGF levels are upregulated
3- to >10-fold in colorectal cancer patients treated with
bevacizumab (Willett et al., 2005), as well as in renal cellCell 131, 463–475, November 2, 2007 ª2007 Elsevier Inc. 471
cancer patients treated with Sunitinib (Motzer et al., 2006).
Induction of PlGF expression has also been proposed to
contribute to human xenografted tumor recurrence after
immunoradiation therapy (Taylor et al., 2003). Furthermore,
PlGF expression correlateswith the tumor stage, vascular-
ity, metastasis, recurrence, and survival in different malig-
nancies. In this study, aVEGFR-2 and sFlk1 upregulated
plasma PlGF levels in tumor-bearing mice, mimicking the
effect of VEGFRIs in clinical trials. Combination treatment
of aPlGF with aVEGFR-2 and sFlk1 resulted in more sus-
tained tumor growth inhibition than monotherapy with
each agent alone. Thus, not only the upregulation of PlGF
by VEGFRIs, but also the pleiotropic and complementary
mechanisms of aPlGF relative to VEGF or VEGFR-2 selec-
tive inhibitors, suggest that aPlGFmay be useful for mono-
therapy, as well as an adjunct to VEGFRIs.
Resistance to aPlGF?
An important question is how to avoid/minimize resistance
to antiangiogenic agents. Antiangiogenesis is expected to
prune the tumor vasculature, thereby depriving tumor
cells from oxygen and causing tumor necrosis. The resul-
tant hypoxia is, however, a strong stimulus for the expres-
sion of angiogenic cytokines, which induce an angiogenic
rescue program that could evoke resistance to VEGFRIs
(Sweeney et al., 2003). Our studies show that hypoxia up-
regulated PlGF release from tumor cells and that aVEGFR-
2 not only inhibited tumor angiogenesis but also increased
tumor hypoxia and upregulated the production of PlGF
and other angiogenic molecules such as FGF-1, FGF-2,
SDF-1, CXCL1, and MMP-9. Each of these cytokines
can be produced by tumor cells, macrophages, and other
stromal cells and are hypoxia-inducible (Casanovas et al.,
2005; Semenza, 2003). sFlk1 induced a similar angiogenic
rescue program (data not shown).
In contrast, aPlGF did not switch on such an angiogenic
rescue program. Indeed, though aPlGF reduced tumor
vessel density, it did not cause as severe hypoxia and ne-
crosis as aVEGFR-2, suggesting that the residual vascula-
ture permitted a critical threshold of oxygenation. The
larger vascular perfusion area and preserved perfusion in
the residual tumors after aPlGF as compared to
aVEGFR-2 are consistent with such model. Besides the
lower hypoxia, the inhibition of intratumoral macrophage
infiltration may also explain the lack of upregulation of
these angiogenic factors in aPlGF-treated tumors. Also,
aPlGF overruled the effect of aVEGFR-2 on tumor macro-
phage infiltration and, coincidentally, on the upregulation
of VEGF by aVEGFR-2 (although aVEGFR-2 upregulated
tumor VEGF levels, aPlGF/aVEGFR-2 combination nor-
malized VEGF levels again; data not shown). Thus, aPlGF
enhances the antitumor efficacy of aVEGFR-2, yet it
does not increase, but might even decrease, the resis-
tance to aVEGFR-2.
Safety and Therapeutic Profile of aPlGF
The safety of antiangiogenic agents will be a determining
factor for their wider spread use in particular oncological472 Cell 131, 463–475, November 2, 2007 ª2007 Elsevier Inc.indications (children, pregnant women, and patients at
risk for developing VEGFRI-related side affects) and be-
yond oncology. Side effects of VEGFRIs include teratoge-
nicity, pruning of healthy vessels, thrombosis, hyperten-
sion, and other effects. Fetal development depends on
the formation of a vascularized placenta—VEGF is essen-
tial for this process (Carmeliet et al., 1996; Ferrara et al.,
1996). Not surprisingly, therefore, VEGFRIs interrupted
pregnancy by inhibiting angiogenesis in the placenta. In
contrast, aPlGF did not affect fetal development consis-
tent with genetic data that embryos develop normally in
the absence of PlGF (Carmeliet et al., 2001). VEGFRIs
do, however, also cause pruning of quiescent vessels in
healthy tissues because they require VEGF survival sig-
nals for their maintenance. aPlGF did not prune such qui-
escent vessels, presumably not only because these fen-
estrated ECs lack VEGFR-1 (Kamba et al., 2006), but
also because expression of PlGF (unlike VEGF) is negligi-
ble in quiescent tissues in baseline conditions (data not
shown). In addition, aPlGF did not aggravate vessel prun-
ing induced by aVEGFR-2, while the combination more ef-
fectively inhibited tumor angiogenesis and growth. Data
that a VEGF-trap (capturing VEGF, VEGF-B, and PlGF)
did not aggravate the neonatal vascular defects induced
by an anti-VEGF antibody are consistent with our findings
(Malik et al., 2006).
Someof the toxicity of theVEGFRIs has been ascribed to
the deprivation of quiescent ECs from critical VEGF-
dependent survival and maintenance signals, thereby
inducing EC dysfunction, leading to a hypertensive and
prothrombotic state. Indeed, VEGF upregulates the vaso-
dilating nitric oxide and maintains the endothelium in an
antithrombotic state by upregulating tPA and downregu-
lating PAI-1 (Carmeliet et al., 1997). In contrast, PlGF is
only a survival signal for growing ECs, but not for quiescent
vessels (as suggested by the PlGF knockout phenotype),
and is not detectable in healthy vessels. Whatever the
mechanisms, the safety of aPlGF is striking and medically
relevant.
Because of the excellent safety profile, aPlGF could be
combined with VEGFRIs to increase efficacy without
increased toxicity or resistance. Besides, single aPlGF
therapy may also offer novel opportunities for the treat-
ment of pathological conditions, for which the adverse ef-
fects of VEGFRIs may be excessive and prohibitive, such
as cancer in children and young (pregnant) women, or per-
haps in patients at risk for thrombotic, cardiac, or other
complications. Our data also warrant further analysis of
systemic aPlGF treatment for ocular neovascularization
as an alternative to intraocular administration of antiangio-
genic agents.
EXPERIMENTAL PROCEDURES
Generation and Characterization of aPlGF
aPlGFwas selected and produced using in vitro hybridoma cell culture
technologies developed at ThromboGenics NV. aPlGF was purified
from cell culture supernatant by affinity chromatography on ProSep
vA Ultra (Millipore). Affinities of aPlGF were determined by using Bia-
core assays. Competitive inhibition studies were performed by ELISA
on immobilized soluble receptors using biotinylated growth-factor-
specific antibodies (all R&D Systems) and on hVEGFR-1 overexpress-
ing cells using 125I-radiolabeled ligand. aPlGF was used at submolar to
1000-fold molar excess. For FRET analysis, porcine aortic endothelial
(PAE) cells transfected with two plasmids expressing Npn1 fused to
the cyan (ECFP) and the yellow (EYFP) variants of GFP were used.
For VEGFR-1 tyrosine phosphorylation studies, 293T cells overex-
pressing VEGFR-1 were used (Errico et al., 2004).
Pharmacokinetics
Mice were i.p. injected with cold or 125I-radiolabeled aPlGF or
aVEGFR-2. Antibody plasma levels up to 21 days were determined
by ELISA or by counting total and TCA-precipitable radioactivity using
a gamma counter.
In Vitro Migration Assay
Subconfluent cell monolayers were grown in serum-free medium con-
taining microchemotaxis chambers, of which the bottom wells were
filled with diluted chemoattractants. After incubation at 37C for 10 hr,
filters were Giemsa stained and cells were counted.
Syngeneic Tumor Models
106 B16.F10, CT26, EL-4 and Panc02 cells were injected subcutane-
ously (s.c.) When tumors had grown to 100 mm3, mice were treated
with aPlGF, aVEGFR-2 (DC101; ATCC) and isotype control IgG1s,
sFlk1 (via hydroporation) or chemotherapy (used at ED50). For ortho-
topic tumors, 106 Panc02 cells were injected into the head of the pan-
creas via abdominal midline incision, and treatment started when
tumors reached 30 mm3.
sFlk1 Hydroporation
40 mg/mouse of a vector encoding sFlk1 or a control vector (Davidoff
et al., 2002) were suspended in 2.5 ml of Ringer’s solution and injected
into the tail vein. sFlk1 plasma protein levels were determined using
a sVEGFR-2 immunoassay (R&D Systems).
Macrophage Depletion
Clodronate encapsulated liposomes (clodrolip) were administered i.p.
24 hr after tumor cell implantation (100 mg/kg); repeated injections
(50 mg/kg) every fourth day prevented macrophage repopulation
(Zeisberger et al., 2006).
ELISA
Concentrations of PlGF, VEGF, and VEGF/PlGF heterodimers were
quantified using PlGF and VEGF immunoassays (R&D Systems).
Values from cell culturemedia were normalized to end-stage cell count
(pg/106 cells). Similar data were obtained when correcting the data for
protein content.
Histology and Morphometric Analyses
All methods for histology and immunostaining on paraffin and cryosec-
tions have been described (Carmeliet et al., 1996; Luttun et al., 2002b).
The following primary antibodies were used: rat anti-CD31, rat anti-F4/
80/Mac1, rat anti-CD45 (all Becton Dickinson), rabbit anti-LYVE-1 (Cell
Signaling), mouse anti-SMCa actin (Sigma), and rat anti-caspase-3
(Abcam). Signals were detected using fluorescently conjugated
secondary antibodies (Alexa 488 or 546, Molecular Probes) or peroxi-
dase-labeled IgGs (Dako) followed by tyramide signal amplification
(Perkin Elmer, Life Sciences). (Lymph)-angiogenesis and tumor inflam-
mation were assessed by quantification of CD31+ and LYVE-1+ micro-
vascular density, or CD31+, LYVE-1+, and F4/80+ area/total tumor area
using a Zeiss Axioplan microscope with KS300 image analysis
software.qRT-PCR
Quantitative RT-PCR was performed as described (Carmeliet et al.,
2001; Luttun et al., 2002b) using the probes and primers listed in
Table S6.
Hypoxia Assesment and Tumor Perfusion
Tumor hypoxia was detected 2 hr after injection of 60mg/kg pimonida-
zole hydrochloride into tumor-bearing mice. To detect the formation of
pimonidazole adducts, tumor sections were immunostained with
hypoxyprobe-1-Mab1 (Chemicon) following the manufacturer’s in-
structions. Tumor perfusion was analyzed using fluorescent micro-
spheres (Luttun et al., 2002b).
Assessment of the Safety Profile of aPlGF
Female Swiss mice were treated with aPlGF, aVEGFR-2, control IgG1,
or sFlk1 for 3 weeks. Tracheal vessel patency was assessed by in vivo
injection of FITC-labeled Lycopersicon esculentum lectin. Tracheas
were removed, immersed in fixative for 1 hr and processed as whole
mounts for immunohistochemistry (Kamba et al., 2006). Capillary
branching points per unit area overlying the cartilage rings were
counted. Vascular density in paraffin sections of thyroid was ex-
pressed as a number of capillary profiles per millimeter of follicle pe-
rimeter. PAI-1 plasma levels were determined by ELISA (Declerck
et al., 1995), and blood pressure was assessed by intraluminal hemo-
dynamic measurements.
Statistics
Data represent mean ± SEM of representative experiments unless oth-
erwise stated. Statistical significance was calculated by Student’s
t test or ANOVA where indicated (Prism v4.0b), considering p < 0.05
as statistically significant. IC50 was calculated using WinNonlin v5.1.
Supplemental Data
The Supplemental Data include five supplemental notes, four supple-
mental figures, six supplemental tables, and Supplemental Experi-
mental Procedures, and can be found with this article online at
http://www.cell.com/cgi/content/full/131/3/463/DC1/.
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